The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•7 May 2026•

1 min read

hVIVO Shares Jump 7% After Securing £6 Million Clinical Trial Contract

Key Facts

1hVIVO shares rose 7% to 7.99p following the announcement of a new influenza clinical trial agreement.

2The new contract is valued at £6 million with an unnamed biopharmaceutical company.

hVIVO PLC shares surged by 7% to reach 7.99p following the announcement of a new influenza clinical trial agreement. The contract, valued at £6 million, was signed with an unnamed biopharmaceutical company and strengthens the firm's forward order book. Analysts at Cavendish highlighted that this win significantly enhances revenue visibility for 2026, describing it as a 'step change' for the company's financial outlook. This latest price movement brings the stock's year-to-date gains to approximately 25%, reflecting strong investor confidence. The deal underscores hVIVO's growing dominance in the human challenge trial market. As a key player on the London AIM market, the company continues to demonstrate robust operational momentum through strategic contract wins.